yes to China and that's why they pay less upfront given correlating impact on the payback period on lower drug pricing.
Paul made a good fist of it with Alan Kolher IMO, other than his explanation on share price performance (ie missed impact of management crying wolf).
Key take always for me:
- Seems they want to include MRI at baseline, 6 & 12 months for labelling and pricing uplift.
- Safety NO change to rental n600. Research from Proctor on Elimron not cause but disease itself. Irrespective the massive oral overdosing by patients over + 7 years is no way a reflection on how we plan to administer.
- 94% response rate from iPPS
Sharewise Presentation 22/7/24, page-112
-
- There are more pages in this discussion • 28 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
20.0¢ |
Change
-0.015(6.98%) |
Mkt cap ! $70.04M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 21.0¢ | 20.0¢ | $201.6K | 994.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 429247 | 20.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.0¢ | 13806 | 2 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |